# US 11,028,437 B2 · Method for evaluating the risk of drug hypersensitivity reaction induced by Sulfamethoxazole and Trimethoprim

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,028,437 B2
- Document ID: US11028437B2
- Status: Granted
- Kind: B2
- Application number: 16/374,651
- Filed: 2019-04-03
- Published: 2019-07-25
- Granted: 2021-06-08
- Earliest claimed: 2016-10-27
- Assignees: Chang Gung Memorial Hospital, Linkou
- Applicants: Chang Gung Memorial Hospital, Linkou
- Inventors: Wen-Hung Chung; Shuen-Iu Hung
- Web page: https://patentgrep.com/patent/US11028437B2

## CPC

- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12Q 1/025: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/166: Oligonucleotides used as internal standards, controls or normalisation probes
- C12Q 2600/172: Haplotypes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided is a method for evaluating the risk of drug hypersensitivity reaction induced by antibiotics sulfamethoxazole and/or trimethoprim. The drug hypersensitivity reaction comprises: maculopapular eruption, fixed drug eruption, Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms. A specific HLA genotype is associated with the drug hypersensitivity reaction induced by the antibiotics sulfamethoxazole and/or trimethoprim.

## Claims

### Claim 1

A method for treating an indication in a patient treatable by sulfamethoxazole and/or trimethoprim, comprising:
evaluating the risk of developing a drug hypersensitivity reaction caused by sulfamethoxazole and trimethoprim in a patient with an indication treatable by sulfamethoxazole and trimethoprim, comprising the step of detecting the presence of HLA-B*1301 allele from a sample from the patient, wherein the presence of the HLA-B*1301 allele indicates the patient has a higher risk of developing drug hypersensitivity reaction caused by sulfamethoxazole and trimethoprim compared to a subject without the HLA-B*1301 allele; and thereafter
based on the detecting the presence of HLA-B*1301 allele from the sample from the patient, administering an antibiotic other than sulfamethoxazole and/or trimethoprim in order to minimize the risk developing a drug hypersensitivity reaction caused by sulfamethoxazole and trimethoprim,
wherein said patient is of Asian ancestry and said drug hypersensitivity reaction caused by sulfamethoxazole and trimethoprim is maculopapular eruption, fixed drug eruption, Stevens-Johnson syndrome, toxic epidermal necrolysis or drug rash with eosinophilia and systemic symptoms.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the drug hypersensitivity reaction is a severe cutaneous adverse drug reaction.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the presence of HLA-B*1301 is detected in the DNA, RNA, proteins, cells or serum from the peripheral blood of the patient.